The genetic basis of the endocannabinoid system and drug addiction in humans

Journal of Psychopharmacology

Volumn 26, Issue 1, 2012, Pages 133-143

  López Moreno, Jose Antonio ^a   Echeverry Alzate, Victor ^a   Bühler, Kora Mareen ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cannabinoid; CNR1; drug addiction; FAAH; genetic polymorphism; human; SNP

Indexed keywords

AMPHETAMINE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE;

CHROMOSOME 1; CHROMOSOME 1P; CHROMOSOME 6; CHROMOSOME 6Q; CHROMOSOME BAND; CNR1 GENE; DRUG DEPENDENCE; ETHNICITY; FAAH GENE; GENE; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

AMIDOHYDROLASES; ANIMALS; ENDOCANNABINOIDS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB1; SUBSTANCE-RELATED DISORDERS;

EID: 84856486914     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111416689     Document Type: Review

References (70)

1. Agrawal A, Wetherill L, Dick DM, et al. Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. Am J Med Genet B Neuropsychiatr Genet. 2009 ; 150: 736-740
2. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol. 1999 ; 58: 315-348 (Pubitemid 29230000)
3. Arnold JC. The role of endocannabinoid transmission in cocaine addiction. Pharmacol Biochem Behav. 2005 ; 81: 396-406 (Pubitemid 40812406)
4. Ballon N, Leroy S, Roy C, et al. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J. 2006 ; 6: 126-130
5. Barrero FJ, Ampuero I, Morales B, et al. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J. 2005 ; 5: 135-141 (Pubitemid 40468120)
6. Basavarajappa BS. Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett. 2007 ; 14: 237-246 (Pubitemid 46376854)
7. Bearden CE, Jasinska AJ, Freimer NB. Methodological issues in molecular genetic studies of mental disorders. Annu Rev Clin Psychol. 2009 ; 5: 49-69
8. Benyamina A, Kebir O, Blecha L, Reynaud M, Krebs MO. CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-analysis. Addict Biol. 2011 ; 16: 1-6
9. Bosier B, Muccioli GG, Hermans E, Lambert DM. Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol. 2010 ; 80: 1-12
10. Chen X, Williamson VS, An SS, et al. Cannabinoid receptor 1 gene association with nicotine dependence. Arch Gen Psychiatry. 2008 ; 65: 816-824 (Pubitemid 351957707)
11. Chiang KP, Gerber AL, Sipe JC, Cravatt BF. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet. 2004 ; 13: 2113-2119 (Pubitemid 39377833)
12. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrié P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol. 2002 ; 13: 451-463 (Pubitemid 35178842)
13. Colombo G, Vacca G, Serra S, Carai MA, Gessa GL. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats. Eur J Pharmacol. 2004 ; 498: 119-123 (Pubitemid 39208070)
14. Colombo G, Serra S, Vacca G, Carai MA, Gessa GL. Endocannabinoid system and alcohol addiction: pharmacological studies. Pharmacol Biochem Behav. 2005 ; 81: 369-380 (Pubitemid 40807134)
15. Comings DE, Muhleman D, Gade R, et al. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry. 1997 ; 2: 161-168 (Pubitemid 27166036)
16. Covault J, Gelernter J, Kranzler H. Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. Mol Psychiatry. 2001 ; 6: 501-502 (Pubitemid 32772558)
17. Demuth DG, Molleman A. Cannabinoid signalling. Life Sci. 2006 ; 78: 549-563 (Pubitemid 41785760)
18. Dlugos AM, Hamidovic A, Hodgkinson CA, Goldman D, Palmer AA, de Wit H. More aroused, less fatigued: fatty acid amide hydrolase gene polymorphisms influence acute response to amphetamine. Neuropsychopharmacology. 2010 ; 35: 613-622
19. Fernández-Ruiz J, Hernández M, Ramos JA. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther. 2010 ; 16: 72-91
20. Filbey FM, Schacht JP, Myers US, Chavez RS, Hutchison KE. Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues. Neuropsychopharmacology. 2010 ; 35: 967-975
21. Flanagan JM, Gerber AL, Cadet JL, Beutler E, Sipe JC. The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet. 2006 ; 120: 581-588 (Pubitemid 44669791)
22. Forget B, Coen KM, Le Foll B. Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration-comparison with CB(1) receptor blockade. Psychopharmacology (Berl). 2009 ; 205: 613-624
23. Freund RK, Gerhardt GA, Marshall KE, Palmer MR. Differences in norepinephrine clearance cerebellar slices from low-alcohol-sensitive and high-alcohol-sensitive rats. Alcohol. 2003 ; 30: 9-18 (Pubitemid 36871712)
24. Gardner EL. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav. 2005 ; 81: 263-284 (Pubitemid 40807127)
25. Gerdeman GL, Schechter JB, French ED. Context-specific reversal of cocaine sensitization by the CB1 cannabinoid receptor antagonist rimonabant. Neuropsychopharmacology. 2008 ; 33: 2747-2759
26. Hariri AR, Gorka A, Hyde LW, et al. Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function. Biol Psychiatry. 2009 ; 66: 9-16
27. Hartman CA, Hopfer CJ, Haberstick B, et al. The association between cannabinoid receptor 1 gene (CNR1) and cannabis dependence symptoms in adolescents and young adults. Drug Alcohol Depend. 2009 ; 104: 11-16
28. Haughey HM, Marshall E, Schacht JP, Louis A, Hutchison KE. Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. Addiction. 2008 ; 103: 1678-1686
29. Heller D, Schneider U, Seifert J, Cimander KF, Stuhrmann M. The cannabinoid receptor gene (CNR1) is not affected in German i.v. drug users. Addict Biol. 2001 ; 6: 183-187 (Pubitemid 32436734)
30. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990 ; 87: 1932-1936
31. Hopfer CJ, Young SE, Purcell S, et al. Cannabis receptor haplotype associated with fewer cannabis dependence symptoms in adolescents. Am J Med Genet B Neuropsychiatr Genet. 2006 ; 141: 895-901 (Pubitemid 44905444)
32. Hutchison KE, Haughey H, Niculescu M, et al. The incentive salience of alcohol: translating the effects of genetic variant in CNR1. Arch Gen Psychiatry. 2008 ; 65: 841-850 (Pubitemid 351957709)
33. Julian MD, Martin AB, Cuellar B, et al. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience. 2003 ; 119: 309-318 (Pubitemid 36577432)
34. Kaczocha M, Glaser ST, Chae J, Brown DA, Deutsch DG. Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2. J Biol Chem. 2010 ; 285: 2796-2806
35. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997 ; 278: 52-58 (Pubitemid 27446270)
36. Krebs Mo, Leroy S, Duaux E, et al. Vulnerability to cannabis, schizophrenia, the (ATT)n polymorphism of the cannabinoid receptor type 1 (CNR1) gene. Schizophr Res. 2003 ; 53: 72
37. Kreek MJ, Nielsen DA, LaForge K. Genes associated with addiction: alcoholism, opiate and cocaine addiction. Neuromolecular Med. 2004 ; 5: 85-108 (Pubitemid 38391959)
38. Li T, Liu X, Zhu ZH, et al. No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry. 2000 ; 5: 128-130 (Pubitemid 30229425)
39. López-Moreno JA, López-Jiménez A, Gorriti MA, de Fonseca FR. Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors. Curr Drug Targets. 2010 ; 11: 406-428
40. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol. 2005 ; 168: 299-325
41. Maldonado R, Berrendero F. Endogenous cannabinoid and opioid systems and their role in nicotine addiction. Curr Drug Targets. 2010 ; 11: 440-449
42. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006 ; 29: 225-232
43. Martinez-Gras I, Hoenicka J, Ponce G, et al. (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. Eur Arch Psychiatry Clin Neurosci. 2006 ; 256: 437-441 (Pubitemid 44584060)
44. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990 ; 346: 561-564
45. Melis M, Pillolla G, Luchicchi A, et al. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci. 2008 ; 17: 13985-13994
46. Monteleone P, Bifulco M, Maina G, et al. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res. 2010 ; 61: 400-418
47. Moreira FA, Kaiser N, Monory K, Lutz B. Reduced anxiety-like behavior induced by genetic and pharmacological inhibition of the endocannabinoid- degrading enzyme fatty acid amide hydrolyses (FAAH) is mediated by CB1 receptors. Neuropharmacology. 2008 ; 54: 141-150 (Pubitemid 350299416)
48. Morita Y, Ujike H, Tanaka Y, et al. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. Neurosci Lett. 2005 ; 376: 182-187 (Pubitemid 40255306)
49. Nestler EJ. Genes and addiction. Nat Genet. 2000 ; 26: 277-281
50. Onaivi ES, Leonard CM, Ishiguro H, et al. Endocannabinoids and cannabinoid receptor genetics. Prog Neurobiol. 2002 ; 66: 307-344 (Pubitemid 34518288)
51. Pertwee RG. Cannabinoid pharmacology: the first 66 years. J Pharmacol. 2006 ; 147 (Suppl 1). 163-171
52. Piomelli D. The molecular logic of endocannabinoid signaling. Nature Rev Neurosci. 2003 ; 4: 873-884
53. Piomelli D. The endogenous cannabinoid system and the treatment of marijuana dependence. Neuropharmacology. 2004 ; 47 (Suppl 1). 359-367 (Pubitemid 39298277)
54. Proudnikov D, Kroslak T, Sipe JC, et al. Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1. Pharmacogenomics J. 2010 ; 10: 232-242
55. Rodríguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 2005 ; 40: 2-14
56. Ryberg E, Vu HK, Larsson N, et al. Identification and characterization of a novel splice variant of the human CB1 receptor. FEBS Lett. 2005 ; 579: 259-264 (Pubitemid 40023406)
57. Schacht JP, Selling RE, Hutchison KE. Intermediate cannabis dependence phenotypes and the FAAH C385A variant: an exploratory analysis. Psychopharmacology (Berl). 2009 ; 203: 511-517
58. Scherma M, Fadda P, Le Foll B, et al. The endocannabinoid system: a new molecular target for the treatment of tobacco addiction. CNS Neurol Disord Drug Targets. 2008 ; 7: 468-481
59. Schmidt LG, Samochowiec J, Finckh U, et al. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend. 2002 ; 65: 221-224 (Pubitemid 34159069)
60. Schroth GP, Chou PJ, Ho PS. Mapping Z-DNA in the human genome. Computer-aided mapping reveals a nonrandom distribution of potential Z-DNA-forming sequences in human genes. J Biol Chem. 1992 ; 267: 11846-11855
61. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci U S A. 2002 ; 99: 8394-8399 (Pubitemid 34651063)
62. Solinas M, Goldberg SR, Piomelli D. The endocannabinoid system in brain reward processes. Br J Pharmacol. 2008 ; 154: 369-383 (Pubitemid 351670594)
63. Tsou K, Mackie K, Sañudo-Peña MC, Walker JM. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience. 1999 ; 93: 969-975 (Pubitemid 29341643)
64. Tyndale RF, Payne JI, Gerber A, Sipe J. The fatty acid amide C385A (P129T) missense variant in cannabis user: studies of drug use and dependence in Caucasians. Am J Med Genet B Neuropsychiatry Genet. 2007 ; 5: 660-666 (Pubitemid 47077151)
65. Van den Wildenberg E, Janssen RG, Hutchison KE, van Breukelen GJ, Wiers RW. Polymorphisms of the dopamine D4 receptor gene (DRD4 VNTR) and cannabinoid CB1 receptor gene (CNR1) are not strongly related to cue-reactivity after alcohol exposure. Addict Biol. 2007 ; 12: 210-220 (Pubitemid 46753648)
66. Vlachou S, Nomikos GG, Panagis G. Effects of endocannabinoid neurotransmission modulators on brain stimulation reward. Psychopharmacology (Berl). 2006 ; 188: 293-305 (Pubitemid 44387457)
67. Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem. 2006 ; 281: 36569-36578 (Pubitemid 46049797)
68. Yates ML, Barker EL. Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. Mol Pharmacol. 2009 ; 76: 11-17
69. Zuo L, Kranzler HR, Luo X, Covault J, Gelernter J. CNR1 variation modulates risk for drug and alcohol dependence. Biol Psychiatry. 2007 ; 62: 616-626 (Pubitemid 47314382)
70. Zuo L, Kranzler HR, Luo X, et al. Interaction between two independent CNR1 variants increases risk for cocaine dependence in European Americans: a replication study in family-based sample and population-based sample. Neuropsychopharmacology. 2009 ; 34: 1504-1513